Latham & Watkins Advises Leading Stem Cell Biotech Mesoblast on Refinancing of Up to US$125 Million

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, has announced that it has repaid in full its existing senior secured loan from Oaktree Capital Management, Inc. and in part its subordinated royalty facility from NovaQuest Capital Management LLC by drawing down US$75 million from a new five-year facility provided by existing Mesoblast shareholder and director Dr. Gregory George. A second tranche of up to US$50 million is available to be drawn at Mesoblast’s option until June 30, 2026.

Latham & Watkins LLP represented Mesoblast Limited in the transaction with a US finance team led by partner Haim Zaltzman, with associates Hyunji Lee and William Lane. Advice was also provided on tax matters by Partner Eric Cho, with associate Sam Yang; and on UK finance matters by partner James Chesterman, with associates Chris Attrill and Kathleen Teo.